Amarantus Announces Positive Preclinical Data on the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa

SAN FRANCISCO and GENEVA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). MANF was discovered utilizing Amarantus' proprietary PhenoGuard™ Protein Discovery Engine.

The aim of the study was to evaluate the efficacy of protecting visual acuity by a single intravitreal injection of MANF in the rd10/rd10 genetic mouse model of RP. These animals carry a spontaneous missense point mutation in Pde6b (cGMP phosphodiesterase 6B, rod receptor, beta polypeptide). Mutations in this gene are found in human autosomal recessive RP. Visual acuity was determined by measuring the spatial frequency threshold by optokinetic tracking. This method allows for a non-invasive assessment of visual acuity in rodents and higher species, including humans.

A single intravitreal administration of MANF after the onset of retinal degeneration on Day 31 resulted in a statistically significant protective effect on visual acuity on Day 38 and Day 45, as compared to vehicle treated animals. This is the first observation of MANF providing a functional benefit on vision in a model of RP. These data complement previously announced effects of MANF on preserving retinal morphology in RP models. The experiments were conducted at a leading ophthalmology contract research laboratory.

"Our results are the first observation of protection of vision in an RP model by MANF, and add a seminal functional visual acuity readout to the initial morphological protection findings reported from the University of Miami's Bascom Palmer Eye Institute," said Dr. David A. Lowe, President & CEO of NeuroAssets and member of the Amarantus Board of Directors. "These data further support our focus on ophthalmic orphan indications, as exemplified by our recent application to the FDA for orphan designation in RP."

In October 2014, the Company applied to the U.S. Food & Drug Administration for Orphan Drug Designation for MANF in RP. The Company expect to receive a response in the near future.

"These promising data provide a compelling basis to continue the further development of MANF in RP towards first-in-man studies," said Gerald E. Commissiong, President & CEO of Amarantus. "We will continue moving forward with a strategic development plan focused initially on orphan ocular diseases, where we see tremendous potential for MANF. We are hopeful to develop better treatments for patients suffering from diseases that lead to blindness due to an array of medical conditions. Ultimately, we believe proof of concept for MANF in human studies in ocular diseases will support MANF development in other therapeutic areas where significant compelling pre-clinical efficacy data has been published and confirmed by independent groups, as well as the Company's own datasets. We firmly believe MANF has blockbuster potential in ophthalmology, neurology, cardiology and metabolic disorders, including diabetes."

About Retinitis Pigmentosa

Retinitis Pigmentosa (RP) refers to a group of inherited diseases involving retinal degeneration. The cell-rich retina lines the back inside wall of the eye and is responsible for capturing images from the visual field. People with RP experience a gradual decline in their vision because photoreceptor cells (rods and cones) die. Symptoms include a progressive degeneration of peripheral and night vision as well as the degeneration in color perception and central vision; night blindness is one of the earliest and most frequent symptoms of RP. RP is typically diagnosed in adolescents and young adults. The rate of progression and degree of visual loss varies from patient to patient, with most people with RP becoming legally blind by age 40. There are approximately 100,000 patients in the United States, 100,000 patients in Europe and 50,000 patients in Japan diagnosed with RP, qualifying it as an orphan indication. There are currently no approved treatments in the market. It is estimated that RP is a multi-billion dollar market opportunity.

About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.

MANF's current lead indication is Retinitis Pigmentosa, and other applications including Parkinson's disease, Diabetes and Wolfram's Syndrome. Additional applications for MANF may include Alzheimer's disease, Traumatic Brain Injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's disease Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test ® ") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain and ophthalmic disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard™"). In November 2014, AMBS entered into an exclusive option agreement with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to acquire Cutanogen Corporation, a subsidiary of Lonza Walkersville, to develop Engineered Skin Substitute (ESS-W), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe burns. For further information please visit www.Amarantus.com , or connect with the Company on Facebook , LinkedIn , Twitter and Google+ .

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

Investor and Media Contact: Jenene Thomas Jenene Thomas Communications, LLC Investor Relations and Corporate Communications Advisor T: (US) 908.938.1475 E: Shareholder Contact: Aimee Boutcher, Investor Relations T: (US) 408.737.2734 x 101 E: Media Contact: Planet Communications Deanne Eagle, Media Contact T: (US) 917.837.5866

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 57

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 65

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market

Updated Category News Views 135

A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 113

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
iFLYTEK’s AINOTE Discounts Put E-Ink Utility on Trial

Updated Category News Views 75

A slim E-Ink notebook is getting shoved into the Black Friday brawl, and iFLYTEK is betting that less screen glare and more follow-through can still command a serious price. The company has put discounts of up to 25% on its AINOTE lineup, a sensible move in a gadget season where buyers have no shortage of tablets, voice apps, and half-used productivity subscriptions...

Continue Reading
Luxor Targets Device Chaos With Kwik IQ Hub Lockers

Updated Category News Views 86

A dead scanner at shift change can make an expensive digital rollout look downright foolish. Luxor Workspaces is aiming squarely at that unglamorous mess with its newly available Kwik IQ Hub smart-locker collection, introduced at the Connected Worker: Manufacturing Summit in Chicago on October 13–15. The pitch is not flashy: put shared radios, scanners, headsets,...

Continue Reading
Resolve Adds Cahaba in Birmingham Pain-Care Expansion

Updated Category News Views 198

Pain-care consolidation has a peculiar way of looking tidy in a release and messy in the real world. Resolve Pain Solutions announced on November 18, 2026, that it has acquired Cahaba Pain and Spine Care, an established provider serving greater Birmingham, Alabama. On its face, this is a straightforward expansion move: buy a respected local practice, retain its physician...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Update on Scully Royalty's Annual Meeting Plans

Updated Category News Views 129

Insightful Overview of Scully Royalty's Annual Meeting Scully Royalty Ltd. (NYSE: SRL) has recently provided valuable insights regarding its upcoming annual general meeting (AGM) scheduled for December 27, 2025. This update follows a noteworthy event involving MILFAM LLC, which filed a purported dissident proxy circular aimed at nominating five candidates for the...

Continue Reading
How a $1,000 Bitcoin Investment Shaped Financial Perspectives

Updated Category News Views 353

The Shift in Bitcoin's Investment Landscape Cryptocurrency has turned into a financial wild west, where fortunes are made and lost at lightning speed. At the center of this universe is Bitcoin, once brushed off by many traditional financiers. One such critic was Jamie Dimon, CEO of JPMorgan & Chase, who didn't hold back his disdain for the digital currency. Dimon’s...

Continue Reading
Netcompany's Share Buyback Program Progress Report

Updated Category News Views 162

Overview of Netcompany's Share Buyback Program In a strategic move to optimize its capital structure, Netcompany Group A/S has initiated a significant share buyback program aiming to repurchase up to DKK 250 million worth of shares. This action is accompanied by a target to acquire a maximum of 1,300,000 shares, reflecting Netcompany's commitment to fulfilling its...

Continue Reading
Ramaco Resources Partners with Goldman Sachs for Minerals Initiative

Updated Category News Views 133

Collaboration with Goldman Sachs Ramaco Resources, Inc. (NASDAQ: METC, METCB) has taken a significant step forward by teaming up with Goldman Sachs & Co. LLC. This partnership aims to establish a new initiative focused on creating a Strategic Critical Minerals Terminal (SCMT) at Ramaco's Brook Mine facility. Strategic Importance of the SCMT The SCMT initiative, approved...

Continue Reading
Understanding V2X's Upgrade to Buy: Key Insights Revealed

Updated Category News Views 96

Understanding V2X's Current Market Position V2X VVX has recently caught the eye of investors after being upgraded to a "Buy" rating. This upgrade marks a significant shift in earnings estimates, which are pivotal in determining stock valuations. The improved earnings outlook reflects a growing sense of optimism among analysts, boosting the overall attractiveness of the...

Continue Reading